Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.30 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24499296 | 0.83 | CDK1 (0.35) | ALDH1A1 | |
| SCHEMBL12091515 | 0.76 | ENPP2 (0.41) | ALDH1A1ENPP2GPR119PTGS2LOXL2 | |
| SCHEMBL1641567 | 0.73 | ENPP2 (0.37) | ENPP2GPR119PTGS2LOXL2LOX | |
| SCHEMBL24499289 | 0.72 | — | — | |
| SCHEMBL24824445 | 0.71 | ENPP2 (0.36) | ENPP2PTGS2LOXL2LOXMAP4K4 | |
| SCHEMBL1641639 | 0.71 | SMN1; SMN2 (0.37) | ALDH1A1ENPP2GPR119PTGS2SMN1; SMN2 | |
| SCHEMBL27352424 | 0.71 | PTGS2 (0.39) | ENPP2PTGS2 | |
| SCHEMBL13241045 | 0.71 | ENPP2 (0.36) | ENPP2PTGS2LOXL2LOX | |
| SCHEMBL12614860 | 0.71 | ENPP2 (0.46) | ENPP2PTGS2LOXL2LOXMAP4K4 | |
| SCHEMBL1641672 | 0.71 | TP53 (0.42) | ENPP2LOXL2LOXMAP4K4PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995090-B2 | Substituted dihydrobenzofuran glycosidase inhibitors | ASCENEURON SA (CH) | 2021-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10995090-B2 | Substituted dihydrobenzofuran glycosidase inhibitors | GAA, ENGASE, BACE1 | ALDH1A1 403/4885ENPP2 1592/4885GPR119 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.